Buy Dilantin

Dilantin

What is Dilantin?

Dilantin is a brand-name medication that contains phenytoin as its active ingredient. Phenytoin belongs to the neurologic class of antiepileptic drugs and is used primarily to control seizures. In Hong Kong, Dilantin is a prescription-only product (Rx) regulated by the Hong Kong Department of Health and is marketed in 100 mg oral pills.

How Dilantin Works in the Body

Phenytoin stabilises neuronal membranes by inhibiting the rapid influx of sodium ions during the early phase of the action potential. This reduces the spread of abnormal electrical activity that triggers seizures. The drug’s effect generally begins within 1-2 hours after oral administration, reaches peak plasma concentrations in about 4 hours, and has a relatively long elimination half-life (22-28 hours in adults) that supports twice-daily dosing for many patients.

Conditions Treated with Dilantin

Dilantin is approved in Hong Kong for the following indications:

• Generalised tonic-clonic (grand mal) seizures in adults and adolescents.
• Partial (focal) seizures with or without secondary generalisation.
• Status epilepticus when rapid seizure control is required (intravenous formulation, not the oral pill discussed here).

These uses are based on regulatory evaluations that consider clinical trial data and decades of practice experience. The medication is typically prescribed for patients who have not achieved adequate seizure control with other antiepileptic agents.

Patient Suitability and Contraindications

Who Should Use Dilantin?

• Adults and adolescents (≥ 12 years) diagnosed with the seizure types listed above.
• Patients with stable liver function, as phenytoin is metabolised primarily by the liver.
• Individuals able to adhere to regular dosing and follow-up blood-level monitoring.

Absolute Contraindications

• Known hypersensitivity to phenytoin or any of the pill’s inactive ingredients.
• Severe sinus-node dysfunction, second- or third-degree atrioventricular (AV) block without a functioning pacemaker.
• Pregnancy (Category D); phenytoin is associated with fetal hydantoin syndrome, neural-tube defects, and other congenital abnormalities. Alternative therapies are preferred whenever feasible.
• Severe hepatic impairment (e.g., Child-Pugh class C) because metabolism is markedly reduced.

Relative Contraindications

• Mild to moderate hepatic disease (dose adjustments and therapeutic drug monitoring are required).
• Elderly patients (greater risk of ataxia, gait disturbances, and drug-interaction complications).
• Concurrent use of other strong cytochrome P450 inducers or inhibitors that may alter phenytoin levels.

Special Populations

• Renal dysfunction: No dose reduction is needed solely for renal impairment, but careful monitoring is advised because metabolites may accumulate.
• Breastfeeding: Phenytoin is excreted in breast milk; clinicians usually assess the risk-benefit ratio before continuation.
• Patients with cardiac conduction disorders: Baseline electrocardiogram (ECG) is recommended before initiating therapy.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Drowsiness, dizziness, and ataxia - usually transient as the body adjusts to steady plasma levels.
• Nystagmus (eye-movement disturbances) - more frequent at higher concentrations.
• Gingival hyperplasia - overgrowth of gum tissue, often managed with excellent oral hygiene and dental visits.
• Hirsutism (excess facial or body hair) - more common in women, may improve after dose reduction.

Serious Adverse Events

• Severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis; immediate discontinuation and emergency care are required.
• Hepatotoxicity - elevated liver enzymes and, rarely, acute liver failure.
• Blood dyscrasias (e.g., leukopenia, thrombocytopenia).
• Cardiac arrhythmias when rapid IV loading is performed (not relevant for the oral pill).

Drug Interactions

• Warfarin - phenytoin induces hepatic metabolism, potentially lowering INR; dose of warfarin may need adjustment.
• Oral contraceptives - increased clearance can reduce contraceptive efficacy; alternative non-hormonal methods are advised.
• Carbamazepine, phenobarbital, rifampin - strong enzyme inducers that lower phenytoin levels, possibly causing loss of seizure control.
• Amoxicillin-clavulanate, sulfonamides - can inhibit phenytoin metabolism, raising plasma concentrations and risk of toxicity.
• Alcohol - acute intake may increase phenytoin levels, while chronic use may have the opposite effect; moderation is prudent.

Food and Lifestyle Interactions

• Alcohol - as noted above, avoid binge drinking.
• High-protein meals - may slightly affect absorption but generally have minimal clinical impact.
• Driving or operating machinery - use caution until the individual knows how Dilantin affects coordination and alertness.

Note: Patients should disclose all prescription medicines, over-the-counter drugs, supplements, and herbal products to their healthcare provider before starting Dilantin.

How to Take Dilantin

• Standard adult dosing: The usual regimen begins with 100 mg taken three times daily (total 300 mg per day). Dosage may be increased by 100 mg increments every 1-2 weeks until seizure control is achieved, not exceeding 400 mg per day without specialist guidance.
• Administration: Swallow each 100 mg pill whole with a full glass of water. The tablet can be taken with or without food; taking it with food may reduce gastrointestinal upset for some patients.
• Missed dose: Take the missed tablet as soon as remembered unless the next scheduled dose is within 4 hours. Do not double the dose to make up for a missed one.
• Overdose: Early signs include nystagmus, ataxia, lethargy, and respiratory depression. Seek emergency medical care; treatment is supportive and may include activated charcoal if ingestion was recent.
• Discontinuation: Phenytoin should be tapered gradually (e.g., reducing 30-50 mg every 1-2 weeks) under medical supervision to avoid precipitating breakthrough seizures.

Monitoring and Follow-Up

• Therapeutic drug monitoring (TDM): Serum phenytoin concentrations are measured 7-10 days after initiation or any dose change. The therapeutic range is 10-20 µg/mL; levels above 20 µg/mL increase the risk of toxicity.
• Liver function tests (LFTs): Baseline and periodic LFTs are advisable, especially in patients with pre-existing liver disease.
• Complete blood count (CBC): Periodic monitoring detects rare blood dyscrasias early.
• Dental evaluations: Regular dental check-ups help manage gingival hyperplasia.

Storage and Handling

• Keep the 100 mg pills in their original container, tightly closed, at room temperature (20-25 °C) away from excess heat, moisture, and direct sunlight.
• Do not use the medication after the expiration date printed on the label.
• Dispose of unused tablets according to local pharmacy-take-back programs or follow the Hong Kong Department of Health’s guidelines for safe drug disposal.

Medication-Specific Glossary

Therapeutic drug monitoring

Measurement of blood phenytoin levels to ensure they remain within the therapeutic range (10-20 µg/mL) for optimal seizure control and safety.

Gingival hyperplasia

Overgrowth of the gum tissue that can occur with long-term phenytoin use, often managed with meticulous oral hygiene and dental care.

Stevens-Johnson syndrome

A rare but life-threatening skin reaction characterized by blistering and detachment of the epidermis; immediate discontinuation of phenytoin is required.

CYP450 induction

Phenytoin’s ability to increase the activity of cytochrome P450 enzymes, accelerating the metabolism of other drugs and potentially reducing their effectiveness.

Phenytoin toxicity

A condition marked by excessive drug levels leading to neurological (e.g., ataxia, nystagmus) and cardiac complications; treated by dose reduction or temporary cessation.

Bioavailability

The proportion of an orally administered dose that reaches systemic circulation unchanged; phenytoin’s oral bioavailability is approximately 70-95 % but varies with formulation.

Medical Disclaimer

This article provides educational information about Dilantin and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.